Isofol Medical AB today announced that the United States Patent and Trademark Office has allowed Isofol’s patent No. 12/805,287, covering the use and pharmaceutical composition of [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy.
Isofol provided evidence demonstrating the clear superiority of Modufolin® over folic acid in reducing pemetrexed toxicity.
“I am very pleased that the superiority of Modufolin® has been accepted by the United States Patent and Trademark Office and that this patent has been allowed. It will provide Modufolin® with long-term market exclusivity in this application” said Anders Rabbe, CEO of Isofol Medical.
Modufolin® is currently being evaluated in two Phase I/II studies, in colorectal cancer and in osteosarcoma.
Modufolin® (chemical name [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-based drugs today including leucovorin and levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently being evaluated in clinical Phase 1/II studies.
About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate is Modufolin®. Isofol Medical collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates including leucovorin and levoleucovorin. For more information please visit www.isofolmedical.se
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
Phone: +46 (0)707 646 500
Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.